The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease - Wikidata - wikimedia - TriplyDB

The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease

The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease

http://www.wikidata.org/entity/Q28239367

about

Kynurenines in CNS disease: regulation by inflammatory cytokines Lacritin rescues stressed epithelia via rapid forkhead box O3 (FOXO3)-associated autophagy that restores metabolism Targeting New Candidate Genes by Small Molecules Approaching Neurodegenerative Diseases Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease Kynurenine 3-Monooxygenase: An Influential Mediator of Neuropathology Regulation of protein homeostasis in neurodegenerative diseases: the role of coding and non-coding genes Kynurenines in the mammalian brain: when physiology meets pathology Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Serotonin-kynurenine hypothesis of depression: historical overview and recent developments Huntington's disease: underlying molecular mechanisms and emerging concepts Structural basis of kynurenine 3-monooxygenase inhibition Molecular basis for catalysis and substrate-mediated cellular stabilization of human tryptophan 2,3-dioxygenase GPR35 activation reduces Ca2+ transients and contributes to the kynurenic acid-dependent reduction of synaptic activity at CA3-CA1 synapses Immunological Relevance of the Coevolution of IDO1 and AHR Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites Targeted Deletion of Kynurenine 3-Monooxygenase in Mice: A NEW TOOL FOR STUDYING KYNURENINE PATHWAY METABOLISM IN PERIPHERY AND BRAIN Model of tryptophan metabolism, readily scalable using tissue-specific gene expression data.Modeling Huntington disease in yeast: perspectives and future directions.Copy-number variation of the neuronal glucose transporter gene SLC2A3 and age of onset in Huntington's disease.Drosophila Sirt2/mammalian SIRT3 deacetylates ATP synthase β and regulates complex V activity.A small-molecule screen identifies L-kynurenine as a competitive inhibitor of TAA1/TAR activity in ethylene-directed auxin biosynthesis and root growth in Arabidopsis.Identification of common genetic modifiers of neurodegenerative diseases from an integrative analysis of diverse genetic screens in model organisms Therapeutic approaches to preventing cell death in Huntington disease Targets for future clinical trials in Huntington's disease: what's in the pipeline?Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration.Kynurenic acid is a nutritional cue that enables behavioral plasticity.Extension of life span of Drosophila melanogaster by the inhibitors of tryptophan-kynurenine metabolism.Cold adaptation shapes the robustness of metabolic networks in Drosophila melanogaster.Prognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration, and invasion of human hepatocellular carcinoma.Berberine Attenuated Aging-Accelerating Effect of High Temperature in Drosophila Model.Berberine Prolongs Life Span and Stimulates Locomotor Activity of Drosophila melanogaster.Huntingtons Disease Mice Infected with Toxoplasma gondii Demonstrate Early Kynurenine Pathway Activation, Altered CD8+ T-Cell Responses, and Premature Mortality.Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation.Minocycline effect on life and health span of Drosophila melanogaster Kynurenine Signaling Increases DNA Polymerase Kappa Expression and Promotes Genomic Instability in Glioblastoma Cells.Raman spectroscopy detects melanoma and the tissue surrounding melanoma using tissue-engineered melanoma models.Huntington disease arises from a combinatory toxicity of polyglutamine and copper binding.Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis.β-Defensin Genomic Copy Number Does Not Influence the Age of Onset in Huntington's Disease.Protective Effect of Antioxidants on Neuronal Dysfunction and Plasticity in Huntington's Disease.

P2860

Q21129356-81FA75D0-B55F-4727-8789-ED270649353E Q24609781-E3B158A9-6A10-4E53-8E3B-07578F59D227 Q26771812-7FD84ABD-09B5-4972-AEA8-ACE82179BE5C Q26781849-F551D62A-D2A6-48F5-B386-2F80AECA4D2E Q26782867-4B50AD44-31A1-4759-A1D5-9C4E9D15F983 Q26799208-164C0B98-E82E-4830-8FAC-3CF9A5C24E84 Q27003296-1325EF04-3470-4760-8ECC-AC16F0674F3D Q27005950-C3F32E60-0CA0-440E-8863-E3B475CAB922 Q27012779-FB90EE21-521D-4637-BC87-5D28F4E486AB Q27026255-05B6701C-9D67-409F-A5FF-596C776CBB81 Q27677296-45049ADE-3AD1-4A87-B8DE-D21721B19E2B Q28115713-75997860-974C-419A-85BF-4E88C018283D Q28535496-5BEC7DEA-20D5-477D-8087-C53034FA77D2 Q28654567-12672389-3DDE-41C8-8AA4-877596830CA1 Q28834131-5EACE0BA-29D4-444D-8935-C8C79ABEE528 Q29306917-EE32BF94-D2BF-4854-AC84-6BF75AD7130F Q30678210-3C1F2FBD-2DB5-4703-80D6-9C2AC777BF78 Q33575494-C7AF90CB-D1FF-416F-AC88-1127EAD45F24 Q33649261-D02A53F8-9E69-40DC-83BC-118DF9DE4AF3 Q33937684-A1F55F68-DCD1-4800-A35A-EF458E21FA04 Q34080446-A62A1CE3-59F3-417F-AB6B-379C3578326C Q34158629-C3246996-E2C2-47B5-8715-0241EB94728F Q34411338-2B012B43-86A0-486B-A7DD-C694ED62F17A Q34435001-3AFE003D-19A3-4B34-A10D-2C3421C082FF Q35054916-9B6140EE-35D2-43FC-8280-4F80EFA36BB6 Q35101846-58738167-84FB-404A-BAC7-EC153F074331 Q35694510-ADBE5C4B-27FC-4D33-8277-672890144589 Q35756078-81BF0D1C-52D4-4750-9CED-7FB3A778F288 Q35775787-A8FFAAE7-A283-489E-89D1-6FFD89C8BA09 Q35838657-C4DCC697-CF3C-492E-AC95-EA1FBFE73542 Q35838662-6F717987-09F3-4B27-BAFB-EAD73650C936 Q36128464-6417CAF1-D0E2-496A-A335-BB6604C8F090 Q36236128-28AC40CF-0014-4F6F-9932-5149E13317F4 Q36409142-38326A69-EC3F-4BA7-B9E7-F013FC30A4FF Q36479788-AA9D6F92-39FD-4197-AE65-1A55B8987A12 Q36861803-3DCBAC4B-FE24-4DE6-A8B7-ABA432760362 Q37173062-284CA6B0-55F0-4675-8DEA-A96BDD496B7F Q37602166-772EE1A2-4AA7-4F01-8D20-3B825D46AB1E Q37603963-0895F68F-8D5D-437B-8075-F2504DC7D253 Q37607467-80FA411F-79DD-4FCA-9F12-C867D896B771

P2860

The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease

http://www.wikidata.org/entity/Q28239367

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

The kynurenine pathway modulat ...... model of Huntington's disease

@ast

The kynurenine pathway modulat ...... model of Huntington's disease

@en

The kynurenine pathway modulat ...... model of Huntington's disease

@nl

type

label

The kynurenine pathway modulat ...... model of Huntington's disease

@ast

The kynurenine pathway modulat ...... model of Huntington's disease

@en

The kynurenine pathway modulat ...... model of Huntington's disease

@nl

prefLabel

The kynurenine pathway modulat ...... model of Huntington's disease

@ast

The kynurenine pathway modulat ...... model of Huntington's disease

@en

The kynurenine pathway modulat ...... model of Huntington's disease

@nl

P1433

Q28239367-66CD918A-37EC-4FC1-A1C8-EBBB1FDC7111

P1476

Q28239367-C44A215C-305A-4956-8B8E-C1C73E7E85B5

P2093

Q28239367-0F2579BA-8ACA-4912-BC9F-113EFC829A88

Q28239367-157E9755-540B-4BC8-A0D6-BCE966AC0B69

Q28239367-39F2FD98-36F1-4BA9-AC2D-5E47918613DB

Q28239367-CCFDA802-4606-4AF6-8A47-C626EA273DFC

Q28239367-D3B1409B-49AA-45A4-B136-DE72842043E0

Q28239367-D98EB1D4-5D37-45BD-B2C5-A564AB20C558

Q28239367-EDD4D5FC-FEEB-4B9B-86B8-D5C418E6CA35

P2860

Q28239367-051C8763-330B-4CE7-B482-D5EF1ADA1FC1

Q28239367-0ECF0550-2367-43BA-9882-A2681CCE25C7

Q28239367-15C42AF5-01F0-4144-BB0D-661D88094596

Q28239367-1F02B5D7-0966-404B-B4D5-EC8D37B413CE

Q28239367-28DC8740-D84A-40DC-BBF2-ADEEECB9FF01

Q28239367-2A97441C-A071-47B3-B5E7-E1F06A563CAD

Q28239367-2D6A9AF5-FD98-4317-8E81-FA58A43BE66A

Q28239367-3AB9DFE7-5550-4DAD-B8EF-2CE7686C6A18

Q28239367-453C3F1E-985F-4FDA-AF52-CB52C08A3C95

Q28239367-5371673F-84D1-4AD5-A790-BAAF142DA233

P304

Q28239367-00D1399B-E751-42C4-AE7E-2F10E916D081

P31

Q28239367-AC84E105-235A-4984-B68B-9D9BFDA1D942

P3181

Q28239367-935836DF-C31C-434B-8DE6-E344902DC228

P356

Q28239367-9B3AAB66-06BA-4A32-B308-DBA1AA8BF107

P407

Q28239367-0DF8603C-1EF5-4C3D-BD95-75B8A01D8728

P433

Q28239367-FF9AAF3F-BDF4-43D8-81AB-2DF7AD5CAF7D

P478

Q28239367-3AE2CA88-234E-4B4D-85EA-C38A89A5F5AD

P50

Q28239367-50DA4B96-8012-43BE-A983-F5342C03DBB2

P577

Q28239367-614DBEA3-9F40-4500-8E0A-CBD0A8087CE5

P5875

Q28239367-EFEAA974-D7EA-49F5-879F-5D2A72E35EDD

P698

Q28239367-C716C8AE-8475-4B20-9974-2DC229A9F313

P921

Q28239367-4556A070-B8BD-45BC-A9A9-F38134999837

Q28239367-83E53EB3-4B63-4B4B-8131-238E74DCC81D

P932

Q28239367-0105C6A2-9029-422E-9D42-817FF89915E9

P3181

P356

J.CUB.2011.04.028

P1433

Current Biology

P1476

The kynurenine pathway modulat ...... model of Huntington's disease

@en

P2093

Charalambos P Kyriacou

http://www.w3.org/2001/XMLSchema#string

Edward W Green

http://www.w3.org/2001/XMLSchema#string

Flaviano Giorgini

http://www.w3.org/2001/XMLSchema#string

Korrapati V Sathyasaikumar

http://www.w3.org/2001/XMLSchema#string

Paul J Muchowski

http://www.w3.org/2001/XMLSchema#string

Robert Schwarcz

http://www.w3.org/2001/XMLSchema#string

Susanna Campesan

http://www.w3.org/2001/XMLSchema#string

P2860

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease.

Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS

Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease

Developmental patterns of 3-hydroxykynurenine accumulation in white and various other eye color mutants of Drosophila melanogaster

Early kynurenergic impairment in Huntington's disease and in a transgenic animal model

Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila

Huntington's disease: from molecular pathogenesis to clinical treatment.

The extended life span of Drosophila melanogaster eye-color (white and vermilion) mutants with impaired formation of kynurenine.

Ocular phototoxicity.

P304

961-966

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2892833

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.CUB.2011.04.028

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51186733

http://www.w3.org/2001/XMLSchema#string

P698

21636279

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

3929356

http://www.w3.org/2001/XMLSchema#string